-$0.35 Earnings Per Share Expected for Pulmonx Co. (NASDAQ:LUNG) This Quarter

Wall Street brokerages predict that Pulmonx Co. (NASDAQ:LUNG) will report earnings per share (EPS) of ($0.35) for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Pulmonx’s earnings, with estimates ranging from ($0.35) to ($0.34). Pulmonx posted earnings per share of ($0.27) during the same quarter last year, which would suggest a negative year-over-year growth rate of 29.6%. The company is scheduled to issue its next earnings results on Tuesday, March 1st.

According to Zacks, analysts expect that Pulmonx will report full year earnings of ($1.33) per share for the current year, with EPS estimates ranging from ($1.34) to ($1.33). For the next year, analysts expect that the company will post earnings of ($1.25) per share, with EPS estimates ranging from ($1.44) to ($1.14). Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow Pulmonx.

Pulmonx (NASDAQ:LUNG) last issued its quarterly earnings data on Monday, November 1st. The company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.09. The business had revenue of $13.26 million for the quarter, compared to analyst estimates of $13.36 million. Pulmonx had a negative return on equity of 20.53% and a negative net margin of 98.57%. During the same quarter in the previous year, the company posted ($1.37) EPS.

A number of equities research analysts recently weighed in on LUNG shares. Morgan Stanley reduced their price objective on Pulmonx from $48.00 to $37.00 and set an “equal weight” rating on the stock in a research report on Friday, January 7th. Wells Fargo & Company reduced their price objective on Pulmonx from $56.00 to $55.00 and set an “equal weight” rating on the stock in a research report on Wednesday, November 3rd. Zacks Investment Research lowered Pulmonx from a “buy” rating to a “hold” rating in a research report on Wednesday. Finally, Piper Sandler upgraded Pulmonx from a “neutral” rating to an “overweight” rating and set a $45.00 price target on the stock in a research report on Wednesday, December 8th. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $52.75.

Shares of LUNG stock opened at $27.79 on Monday. Pulmonx has a twelve month low of $27.46 and a twelve month high of $68.76. The company has a debt-to-equity ratio of 0.07, a quick ratio of 9.57 and a current ratio of 10.25. The stock’s fifty day simple moving average is $33.77 and its 200 day simple moving average is $37.59.

In related news, insider Geoffrey Beran Rose sold 7,000 shares of the company’s stock in a transaction dated Monday, November 15th. The stock was sold at an average price of $39.94, for a total transaction of $279,580.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Glendon E. French III sold 25,000 shares of the company’s stock in a transaction that occurred on Thursday, October 21st. The stock was sold at an average price of $39.75, for a total value of $993,750.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 109,159 shares of company stock worth $3,790,514. 12.56% of the stock is owned by corporate insiders.

A number of hedge funds have recently bought and sold shares of LUNG. New York State Common Retirement Fund raised its stake in Pulmonx by 17.6% during the 2nd quarter. New York State Common Retirement Fund now owns 21,893 shares of the company’s stock worth $966,000 after buying an additional 3,283 shares during the period. Arizona State Retirement System purchased a new stake in shares of Pulmonx in the second quarter worth approximately $235,000. Rhumbline Advisers raised its stake in shares of Pulmonx by 93.9% in the second quarter. Rhumbline Advisers now owns 24,343 shares of the company’s stock worth $1,074,000 after purchasing an additional 11,788 shares during the last quarter. Swiss National Bank purchased a new stake in shares of Pulmonx in the second quarter worth approximately $1,910,000. Finally, Ameritas Investment Partners Inc. raised its stake in shares of Pulmonx by 104.6% in the second quarter. Ameritas Investment Partners Inc. now owns 1,991 shares of the company’s stock worth $88,000 after purchasing an additional 1,018 shares during the last quarter. 89.30% of the stock is currently owned by institutional investors and hedge funds.

Pulmonx Company Profile

Pulmonx Corporation, a medical technology company, designs, develops, manufactures, and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console with flow and pressure sensors that are used to assess the presence of collateral ventilation.

Featured Article: What Does a Sell-Side Analyst Rating Mean?

Get a free copy of the Zacks research report on Pulmonx (LUNG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pulmonx (NASDAQ:LUNG)

Receive News & Ratings for Pulmonx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmonx and related companies with MarketBeat.com's FREE daily email newsletter.